Navigation Links
FASgen Announces Significant Milestone in Its Cancer Drug Development Program
Date:10/1/2007

BALTIMORE, Oct. 1 /PRNewswire/ -- FASgen's fatty acid synthase inhibitor (FASi) compounds, led by FAS031, have demonstrated efficacy against every solid tumor xenograft cell line tested, in both orthotopic and flank models: 4 lung tumor cell lines (H460; A549; H1975; LX7); two ovarian; breast; and, colon. In many cases the tumors were eradicated entirely. The compounds have been shown in extensive preclinical studies to be remarkably safe and orally available. One compound was safely given to mice twice a day orally for 6 months with no observed adverse side effects except the elimination of the tumors. Other compounds were given to mice in a two year experiment and prevented the onset of tumors in nearly one-third of the mice. That experiment was repeated with a different compound and produced the same result. Several of these results have been recently published and others will shortly be published in leading oncology journals.

FASi is a new mechanism of action for the treatment of cancer. The fatty acid biosynthesis pathway is critical to all living organisms to produce fat and regulate the body's energy. In cancer cells, FASgen researchers over the last 15 years have discovered that the mechanism acts differently. As cancer cells do not produce fat, the fatty acid biosynthesis pathway in the transformed cell acts to regulate the energy source that keeps the cell alive. One critical enzyme in that pathway is FAS. The Company's researchers have discovered that inhibition of FAS kills the cancer cell, a result that has been recently replicated in a number of labs and become the subject of a series of new publications. FASgen has developed a library of FASi compounds and has an extensive body of intellectual property surrounding both the mechanism of action and uses for the compounds, and of course the composition of individual compounds. "This discovery holds out the prospect for a new method of treatment for cancer that is remarkably safe and may dimi
'/>"/>

SOURCE FASgen, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 19, 2014 In today,s increasingly global ... presence to reflect the needs of a global ... meet the needs of key stakeholders while recognizing ... According to recent research by benchmarking firm, ... participating companies averaged more than $100,000 in annual ...
(Date:12/19/2014)... , Dec. 18, 2014 Somewhere between ... hearing health was forgotten. But Audicus , a ... hear better this new year. Hearing loss ... the aging population, though it is often unaddressed. Forty-eight ... four has a hearing aid, mainly due to price. ...
(Date:12/19/2014)... SAN DIEGO , Dec. 18, 2014  RESMED INC. ... report its second quarter of fiscal year 2015 results on ... market close. A press release with ResMed,s results will be ... will host a webcast to discuss operating results and future ... at 1:30 p.m. US Pacific Time and the live webcast ...
Breaking Medicine Technology:Building a Best-in-Class Pharma Global Brand Website 2Audicus Will Help People Resolve to Hear Better in 2015 2ResMed To Announce Second Quarter 2015 Results 2
(Date:12/22/2014)... CA (PRWEB) December 22, 2014 The ... PALS, BLS and ACLS online certification provider, are proud ... http://www.acls-pals-bls.com . The updated site now features a more ... than ever to use. , As a company ... information is now consolidated into a single page during ...
(Date:12/22/2014)... Harrisburg, NC (PRWEB) December 22, 2014 ... contain the current Ebola virus epidemic are ... by U.S. government agencies, nongovernmental organizations (NGOs) ... solutions remains ongoing, healthcare workers, emergency responders, ... advanced technologies such as the CmTP ...
(Date:12/22/2014)... 22, 2014 Physicians in China are ... the treatment of non-Hodgkin’s lymphoma (NHL), according to a ... global healthcare consulting firm. MabThera is the only biologic ... most common form of NHL. , According to Kantar ... the incidence of NHL in China has been growing ...
(Date:12/22/2014)... Explorys, the leader in big data-driven ... team: Greg Yarrington as Vice President of Operations, Adam ... as Vice President of Solutions. These new leaders are ... in 2015 to support client demand for the company’s ... and growth of its partner network. , Since ...
(Date:12/22/2014)... 2014 In recognition of Veteran’s Day, ... Hero Reward, a local organization that provides services to ... , Located on a couple hundred acres in the ... lodging, world class fishing, hunting, hiking, horseback riding, 4-wheeling, ... several years ago to support U.S. Service men and ...
Breaking Medicine News(10 mins):Health News:ACLS Online Certification Website ACLS-PALS-BLS.com Now Features a New and User-Friendly Layout 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 3Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 4Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 5Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 3Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 3Health News:Discount Labels Donates Portion of November Sales to Hero Reward Program 2
... is expanding its advanced mobile health screening services ... screening equipment and techniques in the industry, HealthYes! screens its ... aortic aneurysm, peripheral artery disease and osteoporosis. , ... ...
... & Liber LLP have been named 2009 Ohio Super Lawyers ... recognizes the law firm,s expertise in personal injury cases and as ... ... Cleveland, Ohio (PRWEB) March 4, 2009 -- Five Cleveland lawyers representing ...
... cervical cancer may direct more women to optimal ... morbidity and complications of trimodality therapy (surgery followed ... the Institute for Technology Assessment in Boston, MA. ... a decision-analytic model to determine the value of ...
... of trauma patients who undergo CT evaluation have incidental ... Corp. at Grant Medical Center in Columbus, OH. ... concern for physicians in regards to the diagnosis and ... out of 1,256 patients (18.3%) who underwent CT of ...
... York, NY (March 3, 2009) A study published in ... (AJN) found that almost 40% of nurses who were ... of misconduct between 2001 and 2005. Nurses on probation ... to recidivate, suggesting that licensing boards should carefully screen and ...
... published in the Journal of Clinical Endocrinology & ... associate professor of clinical medicine and director of the ... increasingly common with age. An estimated 37 million Americans ... of that population. Another 20 to 30 percent of ...
Cached Medicine News:Health News:HealthYes! Now Offering its Preventive Health Screening Services in Houston 2Health News:HealthYes! Now Offering its Preventive Health Screening Services in Houston 3Health News:Cleveland Attorneys Recognized as Ohio Super Lawyers 2Health News:Cleveland Attorneys Recognized as Ohio Super Lawyers 3Health News:Cleveland Attorneys Recognized as Ohio Super Lawyers 4Health News:MRI and PET/CT improve cervical cancer patient's chances for optimal treatment 2Health News:New research in AJN shows link between nurse's criminal history and professional misconduct 2Health News:New research in AJN shows link between nurse's criminal history and professional misconduct 3Health News:'Pre-diabetics' face heightened risk of heart disease 2
For the qualitative detection of cardiac troponin I (cTnl) in human whole blood and serum specimens...
For the qualitative detection of cardiac troponin I (cTnl) in human whole blood and serum specimens...
For the qualitative detection of antibodies to Treponema pallidum in human serum, plasma and whole blood specimens...
For the qualitative detection of antibodies to HIV-1 and HIV-2 in human serum, plasma and whole blood specimens...
Medicine Products: